{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:53:27Z","timestamp":1762430007953},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1053\/j.seminoncol.2004.07.029","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T13:58:14Z","timestamp":1131026294000},"page":"87-91","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S10","title":["Perspectives on the future of bisphosphonate use in breast cancer patients"],"prefix":"10.1053","volume":"31","author":[{"given":"Mark","family":"Clemons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Rea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2004.07.029_bib1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clon.2004.01.004","article-title":"Should all breast cancer patients with symptomatic bone metastases be treated with bisphosphonates? The case in support","volume":"16","author":"Clemons","year":"2004","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib2","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib3","first-page":"e168","article-title":"Do physician follow systemic treatment and funding policy guidelines? A review of bisphosphonate use in patients with bone metastases from breast cancer","volume":"11","author":"Clemons","year":"2004","journal-title":"Can J Clin Pharmacol"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.327.7413.469","article-title":"Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer","volume":"327","author":"Ross","year":"2003","journal-title":"BMJ"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib6","doi-asserted-by":"crossref","first-page":"821","DOI":"10.4065\/75.8.821","article-title":"Prevention and treatment of osteoporosis in women with breast cancer","volume":"75","author":"Mincey","year":"2000","journal-title":"Mayo Clin Proc"},{"issue":"suppl 4","key":"10.1053\/j.seminoncol.2004.07.029_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/bjc.1998.756","article-title":"Aromatase inhibitors and their future role in post-menopausal women with early breast cancer","volume":"78","author":"Lonning","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib8","first-page":"6","article-title":"Effect of exemestane on bone","volume":"23","author":"Lonning","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib9","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0960-0760(03)00350-9","article-title":"\u2018Arimidex\u2019 (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer - Efficacy overview","volume":"86","author":"Buzdar","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib11","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ctrv.2004.03.004","article-title":"Aromatase inhibitors in the adjuvant setting","volume":"30","author":"Clemons","year":"2004","journal-title":"Cancer Treat Rev"},{"issue":"suppl 10","key":"10.1053\/j.seminoncol.2004.07.029_bib13","first-page":"S1","article-title":"2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada","volume":"167","author":"Brown","year":"2002","journal-title":"CMAJ"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib14","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/S0959-8049(01)00317-3","article-title":"Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients","volume":"37","author":"Vehmanen","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib15","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","article-title":"Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer","volume":"90","author":"Powles","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib16","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/bjc.1997.105","article-title":"Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens","volume":"75","author":"Saarto","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/8756-3282(96)00075-0","article-title":"Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer","volume":"18","author":"Rizzoli","year":"1996","journal-title":"Bone"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib18","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.07.029_bib19","first-page":"S31","article-title":"Changes in bone mineral density caused by anastrazole or tamoxifen in combination with goserelin (+\/\u2212 Zoledronate) as adjuvant treatment for hormone receptor positive premenopausal breast cancer","volume":"76","author":"Gant","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0305-7372(02)00095-6","article-title":"The anti-tumour activity of bisphosphonates","volume":"28","author":"Neville-Webbe","year":"2002","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/sj.bjc.6601009","article-title":"Bisphosphonates antagonize bone growth factors\u2019 effects on human breast cancer cells survival","volume":"89","author":"Fromigue","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(79)91551-4","article-title":"Effects of disodium dichloromethylene diphosphate on Paget\u2019s disease of bone","volume":"2","author":"Meunier","year":"1979","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib23","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib25","first-page":"8","article-title":"Adjuvant pamidronate therapy prevents","volume":"23","author":"Kokufu","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/bmj.325.7372.1051","article-title":"Bisphosphonates as adjuvant treatment for breast cancer","volume":"325","author":"Gralow","year":"2002","journal-title":"BMJ"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients","volume":"19","author":"Saarto","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib29","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib30","first-page":"9","article-title":"Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow - A longtime follow-up","volume":"23","author":"Jaschke","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib31","first-page":"9","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer","volume":"23","author":"Powles","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.07.029_bib32","first-page":"8","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment","volume":"23","author":"Saarto","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.07.029_bib33","first-page":"S90","article-title":"The evolving role of bisphosphonates for the prevention of cancer treatment-induced bone loss in patients with breast cancer","volume":"34","author":"Theriault","year":"2004","journal-title":"Bone"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.07.029_bib34","first-page":"S85","article-title":"Zoledronic acid is being investigated for the prevention of bone metastases in patients with early stage breast cancer","volume":"34","author":"Coleman","year":"2004","journal-title":"Bone"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377540400377X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377540400377X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T04:38:01Z","timestamp":1554352681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009377540400377X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":34,"alternative-id":["S009377540400377X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2004.07.029","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}